Home

meloun druhý lžíce bluebird bio stock price Neustálý hluboký Přes

What is Wall Street's Target Price for bluebird bio Inc (BLUE) Stock Monday?
What is Wall Street's Target Price for bluebird bio Inc (BLUE) Stock Monday?

bluebird bio (BLUE) Stock Last 6 Months ($3.07-$7.60)
bluebird bio (BLUE) Stock Last 6 Months ($3.07-$7.60)

bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock

Why bluebird bio (BLUE) Stock Plunged 60% Year to Date?
Why bluebird bio (BLUE) Stock Plunged 60% Year to Date?

bluebird bio Stock Gives Every Indication Of Being Possible Value Trap
bluebird bio Stock Gives Every Indication Of Being Possible Value Trap

BLUEBIRD BIO, INC. : BLUE Stock Price | US09609G1004 | MarketScreener
BLUEBIRD BIO, INC. : BLUE Stock Price | US09609G1004 | MarketScreener

Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets
Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets

bluebird bio Inc (BLUE) Stock 5 Years History [Returns & Performance]
bluebird bio Inc (BLUE) Stock 5 Years History [Returns & Performance]

bluebird bio Inc (BLUE) Stock Price & Performance 2022
bluebird bio Inc (BLUE) Stock Price & Performance 2022

Bluebird Bio Says Cash Crunch Raises 'Going Concern' Risk - Bloomberg
Bluebird Bio Says Cash Crunch Raises 'Going Concern' Risk - Bloomberg

Bluebird extends cash runway to late 2024 with $113M raise
Bluebird extends cash runway to late 2024 with $113M raise

Bluebird Bio Inc. (BLUE:NSD) Analysts rate as a Hold, $5.29 target | Stock Target Advisor
Bluebird Bio Inc. (BLUE:NSD) Analysts rate as a Hold, $5.29 target | Stock Target Advisor

bluebird bio, Inc. announces pricing of $120M public offering of common stock - Medical Buyer
bluebird bio, Inc. announces pricing of $120M public offering of common stock - Medical Buyer

Should You Buy This Growth Stock Following a Major Approval? | The Motley Fool
Should You Buy This Growth Stock Following a Major Approval? | The Motley Fool

bluebird bio, Inc. Announces Proposed Public Offering of Common Stock | Business Wire
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock | Business Wire

Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future | Markets Insider
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future | Markets Insider

Articles with bluebird bio
Articles with bluebird bio

bluebird bio Stock (NASDAQ:BLUE), Quotes and News Summary - Benzinga
bluebird bio Stock (NASDAQ:BLUE), Quotes and News Summary - Benzinga

bluebird bio Inc (NASDAQ:BLUE) sees increased investment from State Street Corp
bluebird bio Inc (NASDAQ:BLUE) sees increased investment from State Street Corp

bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down | Nasdaq
bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down | Nasdaq

BLUE Stock Price - Analyst Update - Stock Target Advisor
BLUE Stock Price - Analyst Update - Stock Target Advisor

What is Wall Street's Target Price for bluebird bio Inc (BLUE) Stock Monday?
What is Wall Street's Target Price for bluebird bio Inc (BLUE) Stock Monday?

1 Reason to Buy Bluebird Bio, and 1 Reason to Sell | Nasdaq
1 Reason to Buy Bluebird Bio, and 1 Reason to Sell | Nasdaq

BLUE Stock Plummets On Clinical Hold, Plans To Exit Europe | Investor's Business Daily
BLUE Stock Plummets On Clinical Hold, Plans To Exit Europe | Investor's Business Daily

BLUE Stock Price and Chart — NASDAQ:BLUE — TradingView
BLUE Stock Price and Chart — NASDAQ:BLUE — TradingView

What 4 Analyst Ratings Have To Say About bluebird bio | Markets Insider
What 4 Analyst Ratings Have To Say About bluebird bio | Markets Insider

BLUE Stock Plummets On Clinical Hold, Plans To Exit Europe | Investor's Business Daily
BLUE Stock Plummets On Clinical Hold, Plans To Exit Europe | Investor's Business Daily

bluebird bio's (BLUE) 52 Week High at $8.49 & Low at $2.94
bluebird bio's (BLUE) 52 Week High at $8.49 & Low at $2.94